Literature DB >> 24765452

Synchronous ovarian carcinoma with colorectal metastases: an unusual presentation.

Kafil Akhtar1, Rana Sherwani1, Afzaal Anees2.   

Abstract

This report describes the case of a 50-year-old female patient who presented with bilateral adnexal lump and dysfunctional uterine bleeding with altered bowel habits. Computed tomography of the abdomen and pelvis revealed a bilateral adnexal lump situated in both the ovaries and a lobular mass of 8 cm in the rectum. Proctoscopy revealed an elevated irregular rectal lesion. The microscopic examination of the ovarian lump revealed a bilateral serous adenocarcinoma with a papillary pattern with psammomatous calcification. A left hemicolectomy with lymphadenectomy was also performed. Immunohistochemical staining was positive for cytokeratin 7 and negative for cytokeratin 20. The use of immunohistochemistry demonstrated the tumor to be of ovarian origin. We report this case of synchronous involvement of the ovary and the colorectum because of its rarity and unusual presentation.

Entities:  

Keywords:  colorectal metastasis; immunohistochemistry.; ovarian cancer

Year:  2012        PMID: 24765452      PMCID: PMC3981276          DOI: 10.4081/cp.2012.e53

Source DB:  PubMed          Journal:  Clin Pract        ISSN: 2039-7275


Introduction

Epithelial cancers represent 90.0% of all malignant ovarian tumors.[1] Primary ovarian cancers tend to spread, at first, within the peritoneal cavity and the omentum, and are frequently associated with ascites, a fluid rich in growth factors and tumor cells disseminated from the primary cancer that fills the peritoneum. Tumor spread to more distant sites, including the contralateral ovary and bilateral ovarian cancers almost always represents a primary tumor and its metastasis rather than dual primary cancers.[2,3] The parallel evolution model suggests that cells with metastatic potential separate from the primary tumor at an early stage in development and evolve independently from the primary tumor.[1] The ovary is a site for a wide range of tumors, both primary and metastatic. Colorectal metastasis from primary ovarian carcinoma account for approximately 4.0% and an isolated rectal metastasis is very rare.[4,5] Morphologically, these tumors mimic primary ovarian adenocarcinomas, especially ovarian endometrioid adenocarcinomas. Identification of the correct primary tumor is necessary for an optimal management, including, specific chemotherapy (CT) in advanced stages. Whereas, ovarian adenocarcinomas respond to platinum based CT, cases of colonic adenocarcinomas are candidates for 5-fluorourocil based CT.[6]

Case Report

A 50-year-old female patient presented with bilateral adnexal lump and dysfunctional uterine bleeding with altered bowel habits. Computed tomography of the abdomen and pelvis revealed a bilateral adnexal lump situated in the ovaries of sizes 10×8 cm and 4×3 cm, and a lobular mass of 8 cm at the rectum with peritoneal implants (Figure 1). Proctoscopy showed an elevated irregular lesion with erosions in the rectum. She underwent a total hysterectomy, a bilateral adnexectomy, and a bilateral iliac lymphadenectomy for the bilateral ovarian lumps. Gross features of the ovaries showed capsular breach with presence of solid and cystic areas on cut sections. The microscopic examination revealed a bilateral papillary serous adenocarcinoma with psammomatous calcification (Figure 2). Iliac lymph nodes were positive for tumor cells. The patient also underwent a left hemicolectomy with lymphadenectomy. Biopsy of the lesion showed moderately differentiated adenocarcinoma (Figure 3). The surgical findings revealed an 8.0 cm submucosal tumor in the rectum and invasion from the serosal side. The tumor primarily involved the rectal muscularis propria and subserosa with only focal invasion of the rectal mucosa. The regional lymph nodes were free of any tumors. Peritoneal dissemination was found to be present which corroborated with the computed tomographic findings. The pathological findings of the ovarian tumor specimen were consistent with those of the hemicolectomy specimen. The patient was staged as T3cN1M1 and stage IV, according to TNM and FIGO classification respectively.
Figure 1

Computed tomography of the abdomen revealed a bilateral adnexal lump situated in both the ovaries with peritoneal implants.

Figure 2

Carcinoma Ovary shows papillary serous adenocarcinoma with psammomatous calcification (Hematoxylin & Eosin ×40).

Figure 3

Colorectal carcinoma shows moderately differentiated adenocarcinoma (Hematoxylin & Eosin ×40).

Computed tomography of the abdomen revealed a bilateral adnexal lump situated in both the ovaries with peritoneal implants. Carcinoma Ovary shows papillary serous adenocarcinoma with psammomatous calcification (Hematoxylin & Eosin ×40). Colorectal carcinoma shows moderately differentiated adenocarcinoma (Hematoxylin & Eosin ×40). Immunohistochemical staining was positive for cytokeratin 7 (Figure 4) and negative for cytokeratin 20 (Figure 5). This staining pattern was consistent with that of colorectal metastasis from the original ovarian lesion and immunohistochemistry supported the histological interpretation of a metastatic ovarian carcinoma. Post adjuvant 6 cycles of specific CT in the form of cisplatinum (50 mg) and 5-fluorourocil (100 mg) were administered to our patient and after 6 months of follow up period, she is doing well.
Figure 4

Positive immunohistochemical staining for cytokeratin 7 (Immunostain Cytokeratin 7 × 40).

Figure 5

Negative immunohistochemical staining for cytokeratin 20 (Immunostain Cytokeratin 20 × 40).

Positive immunohistochemical staining for cytokeratin 7 (Immunostain Cytokeratin 7 × 40). Negative immunohistochemical staining for cytokeratin 20 (Immunostain Cytokeratin 20 × 40).

Discussion

Haraoka et al.[5] in an autopsy series, reported that colorectal metastases present with an ovarian origin in about 6.0% of cases and represent about 30.5% of all ovarian cancers. Colorectal metastasis from ovarian cancer is very rare. Koyama et al.[7] have reviewed and reported only 19 such cases since 2005 in Japan. Their patients ranged in age from 34 to 77 years with an average age of 58.8 years. The location was ascending colon in 4 patients, transverse in 2, descending in 5, sigmoid in 5, and rectum in 5. The tumor appearance was protruding in 13 cases, ulcerative in 2, and a submucosal tumor type in 1 of the 14 cases in which the macroscopic appearance was reported. In 9 of the 14 cases in which the tumor protruded, the vertex of the tumor was ulcerated.[7] Therefore, distinguishing colorectal metastasis from ovarian carcinoma and primary colon cancer based on the macroscopic appearance is often difficult.[7] Colorectal metastasis was observed to be synchronous with ovarian carcinoma in 7 patients in a study by Loy et al.,[8] a finding similar to our report. In some cases, elevated levels of tumor markers such as CA-125 and CEA may help to make a correct diagnosis. However, up to 15% of the cases of ovarian carcinoma were present without any elevated levels of serum CA-125.[9] Immunohistological staining is very useful to differentiate the origin. Loy et al.[8] reported a cytokeratin 7 positive/cytokeratin 20 negative immunophenotype to be nearly 100% specific for an ovarian origin. Conversely, a cytokeratin 7 negative/ cytokeratin 20 positive immunophenotype was seen in 94% of the tumors of colonic origin.[10] In our case, the colonic tumor was positive for cytokeratin 7 and negative for cytokeratin 20, a pattern consistent with an ovarian origin rather than a colonic one. In addition, a comparison of the patient's primary ovarian cancer with the colorectal mass revealed that the two tumors have similar histological features. The spread of ovarian cancer to the colorectum can occur in four different ways, hematogenous spread, lymphatic spread, direct invasion and peritoneal dissemination.[3] The most plausible explanation of colorectal involvement in ovarian adenocarcinomas is through intra-peritoneal seedling. Hematogenous spread occurs in advanced peritoneal disease. In a substantial number of autopsy cases of advanced ovarian cancers, Reed et al.[11] identified peritoneal involvement in 83–100% cases, with large intestinal involvement in 50–60% cases. In most cases of bowel metastases, the serosa is affected initially and then invasion extends from serosal and subserosal tissues into the muscularis propria and mucosa of the bowel wall.[12] In the present case, the tumor mainly involved the rectal muscularis propria and subserosa with only focal invasion of the rectal mucosa and invasion of the retroperitoneum. The pattern of metastasis was thought to have spread by the peritoneal route. Certain morphological features indicative of metastasis from colorectum include garland-like tumor necrosis, segmental destruction of glands and absence of squamous metaplasia, whereas cribriform growth patterns and intra-luminal dirty necrosis are indicators of ovarian adenocarcinomas.[10] However, the problem exists in sorting out these tumors, including in cases mucinous adenocarcinomas, when there is simultaneous involvement of the ovary and the colorectum at similar (synchronous) or at different (metachronous) times.[2] Rekhi et al.[12] showed that morphologically, metastatic tumor deposits in the colorectum retained the morphology of ovarian papillary serous cystadeocarcinoma with foci of psammomatous calcification in 6 of their 11 cases. Absence of garland-like tumor and necrosis were pointers towards an ovarian primary, apart from the clinical context of a preceding ovarian tumor in 81.8% such cases.[13] It is thus important to identify whether or not a tumor has an ovarian origin using immunohistochemical markers, since the occurrence of gastrointestinal metastases from ovarian cancer is very rare. As described lately, specific cytokeratin immunemarkers like cytokeratin 7 and cytokeratin 20 have been documented to be helpful in resolving these dilemmatic situations of ovarian involvement by colorectal carcinoma and vice versa. Zighelboim et al.[13] described a single case of atypical sigmoid metastasis from a high-grade ovarian adenocarcinoma, using differential expression of CK7 and 20. O'Hanlan et al.[14] have reported that a longitudinal negative margin of 2–5 cm in the resected bowel along with a wedge resection of mesentery, including paracolic and intermediate-level nodes might be indicated to achieve optimal debulking of gastrointestinal metastases from ovarian carcinomas. Our patient underwent total hysterectomy, bilateral adnexectomy, and bilateral iliac lymphadenectomy with left hemicolectomy and postoperative chemotherapy.

Conclusions

In cases of colorectal involvement by ovarian adenocarcinomas and vice versa, it can be difficult to ascertain an exact primary. In such cases, apart from complete clinical details, histomorphological features like garland-like necrosis, desmoplasia and psammomatous calcification are useful pointers towards exact primary and along with differential expression of cytokeratins 7 and 20 by immunohistochemistry can be helpful in solving these dilemmas.
  9 in total

1.  Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988.

Authors:  E Reed; C S Zerbe; O W Brawley; A Bicher; S M Steinberg
Journal:  Am J Clin Oncol       Date:  2000-04       Impact factor: 2.339

2.  [Ovarian metastasis of colorectal adenocarcinomas. A clinico-pathological study of 41 cases].

Authors:  V Lindner; B Gasser; A Debbiche; L Tomb; J M Vetter; P Walter
Journal:  Ann Pathol       Date:  1999-12       Impact factor: 0.407

Review 3.  Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.

Authors:  A F Sobrero; C Aschele; J R Bertino
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

4.  Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection.

Authors:  K A O'Hanlan; S Kargas; M Schreiber; D Burrs; P Mallipeddi; T Longacre; M Hendrickson
Journal:  Gynecol Oncol       Date:  1995-11       Impact factor: 5.482

5.  Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma.

Authors:  T S Loy; R D Calaluce; G L Keeney
Journal:  Mod Pathol       Date:  1996-11       Impact factor: 7.842

6.  Atypical sigmoid metastasis from a high-grade mixed adenocarcinoma of the ovary.

Authors:  Israel Zighelboim; Russel Broaddus; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2004-09       Impact factor: 5.482

7.  Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer--a study on 674 patients.

Authors:  K Takahashi; T Shibukawa; M Moriyama; T Shirai; S Kijima; O Iwanari; I Matsunaga; M Kitao
Journal:  Jpn J Surg       Date:  1986-09

8.  Colon metastasis 20 years after the removal of ovarian cancer: Report of a case.

Authors:  Kotaro Shibahara; Kazuya Endo; Tetuo Ikeda; Hisanobu Sakata; Noriaki Sadanaga; Masaru Morita; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Surg Today       Date:  2009-02-07       Impact factor: 2.549

9.  Clinicopathological features and the value of differential Cytokeratin 7 and 20 expression in resolving diagnostic dilemmas of ovarian involvement by colorectal adenocarcinoma and vice-versa.

Authors:  Bharat Rekhi; Sophia George; Bhulaxmi Madur; R F Chinoy; Rajesh Dikshit; Amita Maheshwari
Journal:  Diagn Pathol       Date:  2008-09-18       Impact factor: 2.644

  9 in total
  3 in total

1.  Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma.

Authors:  Changmei Liu; Fangmei Yang
Journal:  Tumour Biol       Date:  2015-04-19

Review 2.  Secondary metastatic lesions to colon and rectum.

Authors:  Michail Galanopoulos; Filippos Gkeros; Christos Liatsos; Christos Pontas; Apostolis Papaefthymiou; Nikos Viazis; Gerassimos J Mantzaris; Nikolaos Tsoukalas
Journal:  Ann Gastroenterol       Date:  2018-03-03

3.  Preoperative colonoscopy in patients with a supposed primary ovarian cancer.

Authors:  Renata Raś; Edyta Barnaś; Joanna Skręt- Magierło; Anna Drozdzowska; Ewelina Bartosiewicz; Marek Sobolewski; Andrzej Skręt; Krzysztof Gutkowski
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.